<qa>  What is the primary objective of AMG 386?The primary objective is to evaluate the efficacy of AMG 386 in combination with sorafenib as measured by the progression free survival PFS rate at 4 months in subjects with advanced or inoperable hepatocellular carcinoma HCC. 